Status:
COMPLETED
Direct Molecular Characterization of Bacteria From ICU and From the REHAB
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Bacterial Infections
Eligibility:
All Genders
Brief Summary
Investigators aim to directly investigate the molecular properties of bacteria from tracheal and urinary samples routinely taken in intensive care units (ICU) patients.
Detailed Description
Investigators goal is to determine major bacterial activities and properties in the infected patient as a basis for more targeted, efficient antimicrobial discovery. Investigators will determine the a...
Eligibility Criteria
Inclusion
- confirmed infection of lung or urine by one or several members of a defined set of bacterial pathogens (Pseudomonas aeruginosa, E. coli, Klebsiella spp., Serratia marcescens, Enterobacter spp., Acinetobacter baumannii, Staphylococcus aureus, Streptococcus pneumonia
Exclusion
- Proof of a refusal to the general research consent
- No detected bacteria
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2021
Estimated Enrollment :
971 Patients enrolled
Trial Details
Trial ID
NCT03475472
Start Date
February 1 2018
End Date
January 27 2021
Last Update
February 17 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Infectious Diseas and Hospital Epidemiology
Basel, Switzerland, 4031
2
REHAB Basel, Klinik für Neurorehabilitation und Paraplegiologie
Basel, Switzerland, 4055